CAMPBELL, Calif., March 25, 2020 /PRNewswire/ -- BioPharmX
Corporation (NYSE American: BPMX) (the "Company"), a specialty
pharmaceutical company focused on developing innovative medical
dermatology products, received notification on March 24, 2020 from the NYSE American LLC (the
"NYSE American" or "Exchange") that the NYSE American has
determined it will commence proceedings to delist the Company's
stock from its Exchange because the Company did not cure its
non-compliance with certain continued listing standards as set
forth in Section 1003(a)(i)-(iii) of the NYSE American Company
Guide, which requires listed companies to maintain stockholders'
equity of $6.0 million or more if
they have reported losses from continued operations and/or net
losses in their five most recent fiscal years, prior to the
expiration of the cure period. The Company plans to appeal the
delisting notice.
NYSE American will allow the Company's common stock to continue
to be listed and traded on NYSE American during the appeal period.
Following such appeal, a decision by NYSE American will be made and
announced by NYSE Regulation regarding either proceeding with
suspension and delisting or continued trading in the Company's
common stock. The delisting does not affect the Company's business
operations, its pursuit of the merger announced on January 28, 2020 or its Securities and Exchange
Commission reporting requirements.
On January 28, 2020, the Company
and Timber Pharmaceuticals LLC announced they had entered into a
definitive merger agreement. A special meeting of the Company's
stockholders will be held on April 30,
2020 to seek stockholder approval for the merger. Prior to
the consummation of the merger, BioPharmX intends to file an
initial listing application with the NYSE American for the combined
company and expects that the combined company will be in compliance
with applicable rules and regulations of the NYSE American at the
time the merger becomes effective.
About BioPharmX® Corporation
BioPharmX Corporation
(NYSE American: BPMX) is a specialty pharmaceutical company
developing prescription products through its proprietary HyantX™
Topical Delivery System for dermatology indications. To learn
more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statement
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the Company's expectations, plans, intentions, and
strategies. Additional risks are set forth in our filings with the
Securities and Exchange Commission, including those described in
the Company's Annual Report on Form 10-K for the most recent fiscal
year. The forward-looking statements included in this news release
are made only as of the date hereof, and the Company undertakes no
obligation to publicly update such statements. BioPharmX is a
registered trademark of BioPharmX, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biopharmx-receives-notice-of-delisting-from-nyse-american-but-stock-will-remain-trading-301029781.html
SOURCE BioPharmX Corporation